Clinical trials: Lung Disorder
Non Small Cell Lung Cancer
A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
Chemotherapy for patients with non-squamous non-small cell lung cancer. Patients are given folic acid, vitamin B12 and steroids, both before and during treatment, to reduce the side effects associated with pemetrexed.
- Trial name
- NCT00609518
- Testing
- pemetrexed, Folic acid, Vitamin B12
- Where
- 14 sites in Australia, Italy and 2 more
- Volunteers
- 111 people
- Sponsor
- Eli Lilly and Company
Idiopathic Pulmonary Fibrosis
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
To evaluate the safety and tolerability of nalbuphine ER tablets in the study population and to evaluate the effect of NAL ER tablets on the mean daytime cough frequency (coughs per hour) at Day 22 (dose 162 mg BID) as compared…
- Trial name
- CANAL (NCT04030026)
- Testing
- NAL ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Trevi Therapeutics
Nonsquamous Nonsmall Cell Neoplasm of Lung
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed…
- Trial name
- DENALI (NCT02259582)
- Testing
- Pemetrexed, Carboplatin, demcizumab
- Where
- 45 sites in United States, Australia and 3 more
- Volunteers
- 82 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Small Cell Lung Cancer
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of…
- Trial name
- NCT02038647
- Testing
- Alisertib, Paclitaxel
- Where
- 61 sites in United States, Belgium and 8 more
- Volunteers
- 178 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Asthma
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects…
- Trial name
- NCT01165138
- Testing
- Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 70 sites in United States, Germany and 4 more
- Volunteers
- 612 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
The primary purpose of study is to evaluate the treatment effect of tezacaftor in combination with ivacaftor (TEZ/IVA) on chest imaging endpoints using low-dose computed tomography (LDCT) at Week 72, and to evaluate the safety of…
- Trial name
- NCT02730208
- Testing
- Tezacaftor/Ivacaftor, Ivacaftor
- Where
- 9 sites in Australia
- Volunteers
- 41 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Non-Small-Cell Lung Cancer
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of three doses of pembrolizumab (MK-3475) in adult Chinese participants with locally advanced or metastatic non-small-cell lung…
- Trial name
- NCT02835690
- Testing
- Pembrolizumab
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
Respiratory Syncytial Virus Infection
Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production.
- Trial name
- IIRI (NCT00593918)
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Sleep Apnea, Obstructive, Hypertension, Pulmonary
Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.
The objective of the study is to evaluate the effect of continuous positive airway pressure (PAP) therapy on pulmonary arterial (PA) pressures in acute decompensated heart failure (HF) patients with obstructive sleep apnea (OSA).
- Conditions
- Sleep Apnea, Obstructive, Hypertension, Pulmonary, Heart Failure
- Trial name
- ASAP-HF (NCT02963597)
- Testing
- AirSense™ 10 AutoSet, Standard Medical Therapy
- Where
- 2 sites in United States, Germany
- Volunteers
- 21 people
- Sponsor
- Albert Einstein Healthcare Network
COVID19
Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic
The SARS-CoV-2 pandemic has resulted in an international shortage of the nasopharyngeal (NP) swabs used to collect sample for virological testing.
- Trial name
- NCT04368260
- Testing
- Control swab, Prototype swab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Pneumonia, Bacterial
Urease Breath Test for Rapid Characterization of Pneumonia
This is a Phase 1, open label, evaluation of a 13C-urea breath test for the detection of urease-producing bacteria in patient with pneumonia in the emergency department.
- Trial name
- NCT03100760
- Testing
- 13C-urea breath test
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of New Mexico
Healthy Volunteers, Asthma
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants
GSK3772847, an anti-interleukin (IL) 33-receptor monoclonal antibody, is a novel treatment for asthma. The purpose of this study to evaluate the safety and tolerability, PK and PD of single ascending doses of GSK3772847…
- Trial name
- NCT04366349
- Testing
- melrilimab (GSK3772847) 70 milligram (mg), melrilimab (GSK3772847) 140 milligram (mg)
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Embolism
Nudging Provider Adoption of Clinical Decision Support
The central hypothesis of this proposal is that the addition of a theory-informed "nudge" to a clinical decision support (CDS) tool will address identified behavioral barriers to use and significantly improve adoption by…
- Trial name
- NCT05203185
- Testing
- Pulmonary Embolism Risk Kalculator (PERK)
- Where
- 2 sites in United States
- Volunteers
- 1,612 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
NSCLC Non-small Cell Lung Cancer
Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
The objective of the trial is to demonstrate that the addition of neoadjuvant and adjuvant immunotherapy (with the anti-PD-L1 antibody MEDI4736) to standard neoadjuvant chemotherapy (with cisplatin/docetaxel) in primary…
- Trial name
- NCT02572843
- Testing
- MEDI4736 (anti-PD-L1)
- Where
- 19 sites in Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Acute Respiratory Distress Syndrome, Sepsis
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
This study is a multi-center, randomized, partially double-blind, and placebo-controlled Phase Ib clinical trial of inhaled CO (iCO) for the treatment of sepsis-induced acute respiratory distress syndrome (ARDS).
- Trial name
- NCT04870125
- Testing
- Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Brigham and Women's Hospital
Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.
- Conditions
- Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Carcinoma, Squamous Cell, Advanced Solid Tumors
- Trial name
- NCT02834247
- Testing
- TAK-659, Nivolumab
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- Calithera Biosciences, Inc
Osteoarthritis, Knee, Osteoarthritis, Hip
A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform
Post-market prospective, multi-center longitudinal study to determine if mobile application-guided education and exercise paired with accurate and sensitive activity monitoring, captured from consumer wearables, can provide a…
- Trial name
- NCT03737149
- Testing
- mymobility with Apple Watch
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 6,559 people
- Sponsor
- Zimmer Biomet
COVID-19, Coronavirus
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.
- Conditions
- COVID-19, Coronavirus, SARS-CoV-2
- Trial name
- PassItOn (NCT04362176)
- Testing
- pathogen reduced SARS-CoV-2 convalescent plasma
- Where
- 26 sites in United States
- Volunteers
- 974 people
- Sponsor
- Vanderbilt University Medical Center
Lung Cancer
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01107626
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- 434 sites in United States
- Volunteers
- 1,516 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.